Coronavirus

Your daily dose of the clinical news you may have missed.

After hospital discharge, persons who had COVID-19 remained at greater risk of death and myriad adverse health outcomes compared with those who had seasonal flu.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Infections with the JN.1 Omicron descendent have doubled since mid-November and now comprise 1 in 5 cases of COVID-19 in the US.

Vaccination against all 3 cocirculating viruses are lower than this time last year and hospitalizations are up across age groups, according to a CDC Health Advisory.

Restoration of certain bacteria in the gut microbiome may help ameliorate common symptoms associated with long COVID, according to new research.

Physiatrist Abby Cheng, MD, an author of the AAPM&R Long COVID Mental Health Consensus Guidance Statement, discusses why the symptoms can be confusing.

Investigators found that the gender life expectancy gap increased 0.23 years from 2010 to 2019 and 0.70 years from 2019 to 2021.

The finding implies the potential for virus transmission after initial recovery from the infection, according to study authors.

Remdesivir use was associated with increased survival among patients hospitalized with COVID-19 requiring supplemental oxygen across SARS-CoV-2 variants of concern, report researchers.

The mRNA-based combination vaccine candidate for flu and COVID-19 received Fast Track Designation from the US Food and Drug Administration.

IDWeek 2023. The study identified disparities in coverage related to age, race, ethnicity, household income, insurance status, and prior influenza vaccination.

IDWeek 2023. New data shows non-Hispanic Black patients had a 13% lower likelihood of getting the influenza vaccine compared to non-Hispanic White patients.

The study findings on enhanced immunity from a third mRNA-1273 dose and specific population benefits will help build effective public health policy, authors say.

The intranasal delivery and live attenuated form of CoviLiv may strengthen immune response and vaccine acceptance and uptake in populations and regions where both are low.

COVID-19, influenza, and RSV will be the topics of a different types of sessions examining the history, new diagnostics, prevention, and future treatments during IDWeek 2023.

IDWeek 2023: Imagine an intriguing hot topic in infectious disease and you'll find a session or 2 where you can learn more and then choose the next topic, rinse, and repeat.

A 2-question quiz on the ACIP's recommendations on the new COVID-19 monovalent vaccines that provide protection from currently circulating strains.

The Novavax COVID-19 vaccine is refreshed with 2023-2024 formula targeting the XBB.1.5 strain.

Your daily dose of the clinical news you may have missed.

Less than one-quarter of US adults surveyed said they would "definitely" get the shot while 33% stated they would "definitely not" get the new vaccine.

Meta-analysis: Among persons with symptoms of long COVID, respiratory and exercise training were effective but pooled information on safety was "uncertain, imprecise."

Your daily dose of clinical news you may have missed.

As COVID-19 hospitalizations increase at the opening of the respiratory virus season, the first "seasonal" vaccine against the virus is ready for roll-out, says the FDA.